Toxic shock syndrome (TSS) is a toxin-mediated infectious process caused in the vast majority of cases by toxin-producing Staphylococcus aureus or Streptococcus pyogenes [1]. The syndrome is driven by bacterial superantigenic exotoxins, which trigger unconventional polyclonal lymphocyte activation and downstream cytokine-driven illness [1][2]. The provided sources identify toxic shock syndrome toxin-1, staphylococcal enterotoxins, and streptococcal pyrogenic exotoxins among the principal toxins discussed [1].
Disease Profile
BacterialToxic shock syndrome
中毒性休克综合征
Toxic shock syndrome is a rare, life-threatening, toxin-mediated infectious syndrome most often linked to toxin-producing strains of Staphylococcus aureus or Streptococcus pyogenes [1][2]. It is an acute, multisystem illness that can progress rapidly to shock, multiple organ failure, and death [1][2]. Source-backed detail on case detection patterns and population burden is limited in the provided material, but the literature emphasizes that the syndrome may be underdiagnosed when shock occurs in the setting of staphylococcal or group A streptococcal infection [2].
TSS is described as an acute, multisystem illness that often results in multi-organ failure [2]. The review literature notes rapid shock as a major manifestation and indicates that the inflammatory cascade can lead to tissue damage, disseminated intravascular coagulation, organ dysfunction, and death [1][2]. Streptococcal toxic shock syndrome is linked to severe group A streptococcal infection and, most frequently, necrotizing soft tissue infection [1]. The provided sources do not supply a fuller symptom inventory, so source-backed detail on additional clinical signs is not yet available.
Toxic shock syndrome is described as rare and life-threatening in the review literature [1]. The sources characterize it as the most fulminant expression of disease caused by toxin-producing S. aureus and group A streptococci, and note that it may be underdiagnosed in patients with staphylococcal or group A streptococcal infection who present with shock [2]. For streptococcal toxic shock syndrome, a systematic review included 1,918 patients across one randomized trial and 40 observational studies, indicating a substantial but highly selected evidence base [3]. The provided material does not give a broader geographic distribution or routine surveillance burden, so those details are not yet available from source-backed evidence.
The provided sources do not describe a single person-to-person transmission route for toxic shock syndrome. Instead, they link the syndrome to toxin-producing bacterial infections, most commonly involving S. aureus or S. pyogenes, with streptococcal toxic shock syndrome most often occurring in the context of severe group A streptococcal infection and necrotizing soft tissue infection [1][2]. Source-backed detail on specific exposure mechanisms, persistence, or environmental reservoirs is not yet available.
Source-backed higher-risk groups are not comprehensively enumerated in the provided material. The available evidence does note that mortality in streptococcal toxic shock syndrome may be higher in patients aged 65 years or older compared with those aged 18-64 years, although the certainty of evidence was low [3]. The sources also distinguish staphylococcal TSS as menstrual or nonmenstrual, but do not provide enough detail here to define additional risk groups beyond the infection context itself [1].
No primary prevention schedule or population-level prophylaxis is described in the supplied sources. The literature instead emphasizes source control, immediate resuscitation, eradication of toxin production, and antimicrobial treatment with agents that can suppress toxin production as key management principles [1][2]. Because the question asks for prevention in a surveillance context, the evidence here supports exposure and infection control framing rather than a specific preventive protocol [1][2].
In monitoring terms, toxic shock syndrome should be interpreted as a rare but severe toxin-mediated complication of staphylococcal or group A streptococcal infection, particularly when shock and rapid organ dysfunction are present [1][2]. The literature also suggests that cases may be missed when clinicians attribute shock to a more general bacterial infection rather than recognizing toxin-mediated disease [2]. For streptococcal toxic shock syndrome, the available evidence base is largely observational, so surveillance summaries should be cautious about precision in prognosis estimates and should note low certainty where treatment-associated mortality associations are cited [3].
- 1 Atchade E et al. Toxic Shock Syndrome: A Literature Review. Antibiotics (Basel). 2024 Jan 18. PMID: 38247655. doi: 10.3390/antibiotics13010096. PubMed: https://pubmed.ncbi.nlm.nih.gov/38247655/
- 2 Lappin E et al. Gram-positive toxic shock syndromes. Lancet Infect Dis. 2009 May. PMID: 19393958. doi: 10.1016/S1473-3099(09)70066-0. PubMed: https://pubmed.ncbi.nlm.nih.gov/19393958/
- 3 Bartoszko JJ et al. Prognostic factors for streptococcal toxic shock syndrome: systematic review and meta-analysis. BMJ Open. 2022 Dec 1. PMID: 36456018. doi: 10.1136/bmjopen-2022-063023. PubMed: https://pubmed.ncbi.nlm.nih.gov/36456018/
- 4 Toxic-Shock Syndrome. New England Journal of Medicine. 1980. doi: 10.1056/nejm198012183032501. DOI: https://doi.org/10.1056/nejm198012183032501
- 5 Toxic shock syndrome. The American Journal of Forensic Medicine and Pathology. 1981. doi: 10.1097/00000433-198103000-00015. DOI: https://doi.org/10.1097/00000433-198103000-00015
- 6 Toxic Shock Syndrome. Clinical Pediatrics. 1989. doi: 10.1177/000992288902801002. DOI: https://doi.org/10.1177/000992288902801002
Dataset Archive
Supplementary Data | Multi-country disease dataset
Machine-readable multi-country disease dataset (JSON/CSV) with source metadata.
Suggested presentation pattern: cite the data version and coverage window when exporting charts or tables for publication.